Nanosonics Limited (NNCSF)
Nanosonics Limited operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Macquarie Park, NSW, AU. The stock last traded at $2.19, up 0.00% on the session, giving a market capitalisation of $654.6M. On trailing twelve-month figures it carries a trailing P/E of 52.29, a net margin of 9.9%. Its beta of 1.20 implies it has historically moved more than the broad market.
Nanosonics Limited, in conjunction with its subsidiaries, functions as an infection prevention enterprise, serving both Australian and international markets. The company's core activities involve the production and supply of the trophon ultrasound probe disinfector, alongside its complementary consumables and accessories. Furthermore, Nanosonics is committed to the research, development, and market introduction of innovative infection control and decontamination products and related technologies. Its product portfolio features the trophon2, a sophisticated device for high-level disinfection of ultrasound probes; trophon EPR, a specialized low-temperature, high-level disinfection solution specifically for intra-cavity ultrasound transducers; and Nanosonics AuditPro, a comprehensive system for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited maintains its corporate headquarters in Macquarie Park, Australia.
Nanosonics Limited is most often compared with the following Healthcare names: